HER-2 exon 20 insertion	Solid Tumor	HER-2 exon 20 insertion	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: C2 – Inclusion Criteria mobocertinib Sensitive : C2	mobocertinib Sensitive: C2 – Inclusion Criteria mobocertinib Sensitive : C2
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 exon 20 insertion	HER2 Negative Breast Cancer	HER-2 exon 20 insertion	HER2 Negative Breast Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3

HER-2 exon 20 insertion

Associations